Bhasker. S, Sandeep. G, Ranganath YS
Bhasker. S1*, Sandeep. G2 and Ranganath YS3
1Department of Pharmacology, University College of Pharmaceutical Sciences, Kakatiya University, Warangal-506002, Andhra Pradesh.
2Department of Pharmaceutics, J.K.K.M.M.R.F. College of Pharmacy, Komarapalayam, Pin
638183, Namakkal, Tamilnadu
3Department of Pharma. Chemistry, G. Pulla Reddy College of Pharmacy, Mehdipatnam, Hyderabad-500082
Volume - 2,
Issue - 4,
Year - 2009
Cycloxygenases (COX) are the principle enzymes involved in the metabolism of arachidonic acid generating prostaglandins which are the genuine mediators of inflammation and pain. COX are classified into Type-1 and Type-2 which are constitutive and inducible respectively. Recent research has brought into light the possible role of these PGs in the COX-2 cascade of tumor proliferation, angiogenesis and metastasis with significant overexpression. Thus COX-2 can serve as a useful biomarker in the early diagnosis and can be selectively targeted in the tumour cells with greater proven safety. The review deals with the potential role of COX-2 inhibitors in canceling the PG mediated Signaling, the role of COX-2 in different types of cancers. (Lung, Head and Neck, Bladder, Cervical Cancer and Other Oncology applications), the beneficial outcomes of combination therapy of COX-2 inhibitors along with either chemotherapy or radiotherapy. In conclusion a note on future research options for treating neuroblastomas with COX-2 inhibitors was elucidated.
Cite this article:
Bhasker. S, Sandeep. G, Ranganath YS. Future of Cancer Therapy-COX-2 Inhibitors: A Review. Research J. Pharm. and Tech.2 (4): Oct.-Dec. 2009; Page617-620.
Bhasker. S, Sandeep. G, Ranganath YS. Future of Cancer Therapy-COX-2 Inhibitors: A Review. Research J. Pharm. and Tech.2 (4): Oct.-Dec. 2009; Page617-620. Available on: https://rjptonline.org/AbstractView.aspx?PID=2009-2-4-64